Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors from the central anxious system, conolidine modulates alternate molecular targets. A Science Innovations examine discovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabil... https://jacko011nyi5.blogsvila.com/profile